Authors
Stephen L Hauser, Nicolas Strauli, Koji Shinoda, Anastasiia Raievska, Christopher Harp, Harold Koendgen, Heidemarie Kletzl, Ulrike Bonati, Xiaoming Jia, Ann Herman, Ludwig Kappos, Amit Bar-Or
Published in
Neurology(R) neuroimmunology & neuroinflammation. Volume 14. Issue 1. Pages e200665. Epub Nov 12, 2026.
Abstract
Anti-CD20 B-cell-depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS).
Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses.
Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8-4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: -1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a-treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions (p < 0.01). When interferon beta-1a-treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001).
Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.
PMID:
43019492
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0